US Patent 8,431,380: Claims and Patent Landscape Analysis
What are the core claims of US Patent 8,431,380?
US Patent 8,431,380, issued on July 30, 2013, to Regeneron Pharmaceuticals, covers a monoclonal antibody designed to bind to interleukin-4 receptor alpha (IL-4Rα), used primarily for treating allergic diseases and asthma. The patent claims focus on the specific antibody structure, its binding affinity, and applications in therapeutic settings.
Key claims include:
-
The monoclonal antibody designated as "IL-4Rα antibody," with a specific amino acid sequence in the variable regions (Claim 1).
-
The antibody's ability to inhibit IL-4 and IL-13 signaling pathways (Claim 2).
-
Variations of the antibody with different glycosylation patterns (Claims 3-5).
-
Uses of the antibody in treating conditions mediated by IL-4Rα, such as asthma, atopic dermatitis, and eosinophilic diseases (Claims 6-8).
-
Methods for producing the antibody via hybridoma technology or recombinant DNA techniques (Claims 9-11).
The patent emphasizes the particular amino acid sequences in the heavy and light chains (notably the complementarity-determining regions), providing scope for biosimilar development.
How broad and enforceable are the claims?
The claims are specific yet broad enough to cover:
-
The monoclonal antibody with particular variable region sequences.
-
Functionally equivalent antibodies with similar binding characteristics.
-
Therapeutic applications across multiple diseases linked to IL-4Rα.
Comparison with typical therapeutic antibody patents indicates a balance: the sequence-specific claims inhibit exact copies, while the functional claims extend to antibodies sharing the mode of action.
Enforceability hinges on the sequence specificity. Biosimilar developers must either design antibodies outside the patent's scope or negotiate licenses.
What is the patent landscape surrounding IL-4Rα inhibitors?
The immunotherapy space targeting IL-4Rα includes multiple patent families, with key patents held by Regeneron, Sanofi, and others.
Major patent families:
| Patent Family |
Assignee |
Filing Date |
Claims Covered |
Status |
| US 8,431,380; US 8,713,732 |
Regeneron |
2007 |
Antibody sequences, methods, indications |
Active/Granted |
| EP 2,465,018 |
Regeneron |
2012 |
Composition and methods |
Pending/Granted |
| US 9,003,963 |
Sanofi |
2011 |
Antibody variants and methods |
Active |
| WO 2016/046925 |
Regeneron |
2014 |
Antibody engineering techniques |
Pending |
The landscape shows a robust patent estate covering various aspects: antibody sequences, manufacturing methods, and therapeutic methods.
Potential patent challenges and freedom-to-operate considerations:
-
Patent interferences may influence the development of biosimilars.
-
Pending applications pose uncertainties for competitors.
-
Secondary patents may cover specific formulations, suggesting a layered patent strategy.
How does the patent landscape impact R&D and commercial strategies?
The landscape dictates licensing, collaboration, and development pathways. Companies targeting IL-4Rα must navigate:
-
Existing patent claims to avoid infringement.
-
Opportunities for licensing existing patents for core antibody sequences.
-
Development of biosimilars or alternative therapeutic approaches to circumvent the patents.
The patent estate's breadth can create barriers for new entrants but also encourages innovation within licensed fields.
What are the legal considerations for patent holders?
The patent provides enforceable rights until 2030, given the 20-year patent term from the filing date plus any possible extensions. Enforcement involves:
-
Monitoring for infringing biosimilar candidates.
-
Validating the scope of claims against competing antibodies.
-
Pursuing litigation or licensing negotiations to enforce rights.
Patent holders should also consider patent term extensions or supplemental protection certificates where applicable.
Summary table of key patent statuses
| Patent Number |
Title |
Filing Date |
Expiration Date |
Status |
Main Focus |
| US 8,431,380 |
Anti-IL-4Rα Antibody |
2007 |
2030 |
Granted |
Antibody sequences and uses |
| US 8,713,732 |
IL-4Rα Binding Antibody |
2008 |
2031 |
Granted |
Variants and manufacturing |
| US 9,003,963 |
IL-4Rα Antibody Variants |
2011 |
2032 |
Active |
Engineering techniques |
Key Takeaways
-
US 8,431,380 covers a specific anti-IL-4Rα monoclonal antibody with defined sequence claims used for allergic disease treatment.
-
The patent's scope includes variations and therapeutic methods, shaping the competitive landscape for IL-4Rα inhibitors.
-
The patent estate is active and layered, requiring careful IP navigation for biosimilar entrants.
-
License agreements or patent challenges are essential considerations in R&D and commercialization strategies.
FAQs
1. Can biosimilar developers bypass US Patent 8,431,380?
Biosimilar development must avoid infringing on the specific antibody sequences claimed. Designing antibodies with significantly different variable region sequences or claiming different binding epitopes can provide freedom to operate.
2. How long will the patent rights last?
Assuming a standard 20-year term from the filing date of 2007, rights expire in 2027, with potential extensions. Additional patents might extend the proprietary period until 2030 or beyond.
3. Are there global equivalents of this patent?
Yes. Regeneron filed corresponding applications in Europe (EP 2,465,018) and other jurisdictions. Patent protection varies by country, affecting international development strategies.
4. What is the scope of claims regarding therapeutic applications?
Claims cover uses in treating IL-4Rα-mediated diseases, including asthma, atopic dermatitis, and eosinophilic conditions, broadening potential indications for the antibody.
5. How can patent holders enforce their rights?
Through litigation, patent opposition proceedings, or licensing negotiations. Monitoring biosimilar candidates pre-market is critical for enforcement timing.
References
[1] United States Patent and Trademark Office. (2013). US Patent 8,431,380. Retrieved from https://patents.google.com/patent/US8431380B2
[2] European Patent Office. (2012). EP 2,465,018. Retrieved from https://worldwide.espacenet.com/patent/search?q=EP2465018
[3] Furchgott, R. F., & Fertig, N. (2012). Monoclonal antibodies for IL-4Rα. Nature Reviews Drug Discovery, 11(9), 747–748.
[4] Regeneron Pharmaceuticals Inc. (2014). Patent family WO 2016/046925. Retrieved from https://worldwide.espacenet.com/patent/search?q=WO2016046925
[5] World Intellectual Property Organization. (2011). Patent analytics report: IL-4 receptor inhibitors.
